Glioblastoma (GB) is the most common and aggressive tumor of the brain. Genotype-based approaches and independent analyses of the transcriptome or the proteome have led to progress in understanding the underlying biology of GB. Joint transcriptome and proteome profiling may reveal new biological insights, and identify pathogenic mechanisms or therapeutic targets for GB therapy. We present a comparison of transcriptome and proteome data from five GB biopsies (TZ) vs their corresponding peritumoral brain zone (PBZ). Omic analyses were performed using RNA microarray chips and the isotope-coded protein label method (ICPL). As described in other cancers, we found a poor correlation between transcriptome and proteome data in GB. We observed only two commonly deregulated mRNAs/proteins (neurofilament light polypeptide and synapsin 1) and 12 altered biological processes; they are related to cell communication, synaptic transmission and nervous system processes. This poor correlation may be a consequence of the techniques used to produce the omic profiles, the intrinsic properties of mRNA and proteins and/or of cancer- or GB-specific phenomena. Of interest, the analysis of the transcription factor binding sites present upstream from the open reading frames of all altered proteins identified by ICPL method shows a common binding site for the topoisomerase I and p53-binding protein TOPORS. Its expression was observed in 7/11 TZ samples and not in PBZ. Some findings suggest that TOPORS may function as a tumor suppressor; its implication in gliomagenesis should be examined in future studies. In this study, we showed a low correlation between transcriptome and proteome data for GB samples as described in other cancer tissues. We observed that NEFL, SYN1 and 12 biological processes were deregulated in both the transcriptome and proteome data. It will be important to analyze more specifically these processes and these two proteins to allow the identification of new theranostic markers or potential therapeutic targets for GB.

中文翻译：

---

转录组和蛋白质组谱在胶质母细胞瘤中的整合：寻找缺失的环节。

胶质母细胞瘤（GB）是最常见的侵袭性脑肿瘤。基于基因型的方法和转录组或蛋白质组的独立分析已导致在了解GB的基本生物学方面取得了进展。联合转录组和蛋白质组分析可能会揭示新的生物学见解，并确定GB治疗的致病机制或治疗靶标。我们提供了从五个GB活检（TZ）与其相应的肿瘤周围脑区（PBZ）的转录组和蛋白质组数据的比较。使用RNA微阵列芯片和同位素编码的蛋白质标记方法（ICPL）进行了Omic分析。如其他癌症中所述，我们发现转录组和蛋白质组数据之间的相关性很差。我们仅观察到两种通常被放松调节的mRNA /蛋白（神经丝轻型多肽和突触蛋白1）和12种改变的生物学过程。它们与细胞通讯，突触传递和神经系统过程有关。这种不良的相关性可能是由于用于产生卵子图谱的技术，mRNA和蛋白质的内在特性和/或癌症或GB特异现象的结果。有趣的是，对通过ICPL方法鉴定的所有变异蛋白的开放阅读框上游存在的转录因子结合位点的分析显示，拓扑异构酶I和p53结合蛋白TOPORS具有共同的结合位点。在7/11 TZ样品中观察到了其表达，在PBZ中未观察到。一些发现表明TOPORS可能起抑癌作用。它在神经胶质瘤发生中的意义应在以后的研究中加以研究。在这项研究中，我们发现转录组和蛋白质组数据之间的相关性很低，如在其他癌症组织中所述的GB样品。我们观察到转录组和蛋白质组数据中的NEFL，SYN1和12个生物学过程均被放松。重要的是要更具体地分析这些过程和这两种蛋白质，以便鉴定出新的治疗诊断标记或GB的潜在治疗靶标。